Skip to main content
. Author manuscript; available in PMC: 2018 Apr 5.
Published in final edited form as: Diab Vasc Dis Res. 2015 Jan 23;12(2):78–89. doi: 10.1177/1479164114561992

Table 2.

SGLT2 inhibitors approved and dual SGLT1/2 inhibitor under development.

Generic name (trade name) Company SGLT2:SGLT1 selectivity References
Dapagliflozin (Forxiga®/Farxiga®) Bristol-Myers Squibb, AstraZeneca 1242 Bailey et al.,56 Komoroski et al.57 and Merovci et al.58
Canagliflozin (Invokana®) Janssen 155 Polidori et al.59
Empagliflozin (Jardiance®) Boehringer Ingelheim 2680 Perkins and colleagues60–62
Ipragliflozin (Suglat®) Astellas Pharma, Kotobuki 254 Poole and Dungo63
Luseogliflozin (Lusefi®) Taisho Pharmaceutical 1770 Markham and Elkinson64
Tofogliflozin (Apleway®, Deberza®) Kowa Company, Sanofi, Chugai 2912 Nagata et al.65
Sotagliflozin Lexicon Pharmaceuticals 20 Zambrowicz et al.66
HHS Vulnerability Disclosure